Jump to content

Kadhim et al. (2021): Effect of Ginger Tea on Chemotherapy-Induced Nausea and Vomiting among Patients Attending the Oncology Teaching Hospital, Baghdad 2020: Difference between revisions

From CAMIH
No edit summary
No edit summary
 
Line 1: Line 1:
{{Reference
{{Reference
|Reference=Effect of Ginger Tea on Chemotherapy-Induced Nausea and Vomiting among Patients Attending the Oncology Teaching Hospital, Baghdad 2020
|Reference=Publication: Effect of Ginger Tea on Chemotherapy-Induced Nausea and Vomiting among Patients Attending the Oncology Teaching Hospital, Baghdad 2020
}}
}}
{{Study Note}}
{{Study Note}}
Line 57: Line 57:


{{Further points for assessing the study
{{Further points for assessing the study
|power analysis performed=?
|Sample size corresponds to power analysis=?
|Reasons given for samples being too small according to power analysis=?
|Samples sufficiently large=?
|Samples sufficiently large=?
|power analysis performed=?
|reasons given for samples being too small according to power analysis=?
|Ethnicity mentioned=?
|Ethnicity mentioned=?
|Other explanations for an effect besides the investigated intervention=?
|Possibility of attention effects=?
|Possibility of attention effects=?
|Possibility of placebo effects=?
|Possibility of placebo effects=?
|Other reasons=?
|Other reasons=?
|Testing for normal distribution=?
|Correct use of parametric and non-parametric tests=?
|Correct application of statistical tests=?
|Correction for multiple testing=?
|Correction for multiple testing=?
|Measurement of compliance=?
|Measurement of compliance=?
Line 71: Line 72:
|Check whether blinding was successful=?
|Check whether blinding was successful=?
|Consistent reporting in numbers=?
|Consistent reporting in numbers=?
|Comprehensive and coherent reporting=?
|Cross-over=?
|sufficient washout period=?
|sufficient washout period=?
|Tested for carry-over effects=?
|Tested for carry-over effects=?
|Were sequence effects tested=?
|Were sequence effects tested=?
|Comprehensive and coherent reporting=?
|Effect sizes reported=?
|Were side effects systematically recorded=?
|Were side effects systematically recorded=?
|Effect sizes reported=?
|Side effects taken into account in the interpretation of the results=?
|Side effects taken into account in the interpretation of the results=?
|Ethics / CoI / Funding=?
|reasons given for samples being too small according to power analysis=?
|Testing for normal distribution=?
|Correct application of statistical tests=?
|mono- or multicentric=?
|mono- or multicentric=?
|Ethics / CoI / Funding=?
}}
}}
{{Additional Notes
{{Additional Notes
|Additional Notes=?
|Additional Notes=?
}}
}}

Latest revision as of 08:48, 10 September 2024


Reference ↗
Title Publication: Effect of Ginger Tea on Chemotherapy-Induced Nausea and Vomiting among Patients Attending the Oncology Teaching Hospital, Baghdad 2020
Topic Ginger
Author Kadhim, R, Ali, B, Kadhim, M, Mohammed, S
Year 2021
Journal Indian Journal of Forensic Medicine & Toxicology
DOI https://doi.org/10.37506/ijfmt.v15i3.15511

Study Note

Brief summary

Study Design

Prospective / Retrospective Prospective: forward-looking, examples include clinical trials, cohort studies, and long-term observational studies;</br>Retrospective: backward-looking, relying on existing data, examples include case-control studies and retrospective cohort studies Prospective
Monocentric / Multicentric Monocentric: conducted in one center/ hospital; </br>Multicentric: conducted in multiple centers/ hospitals Monocentric
Blinding No: Open, all parties are aware of group assignments;</br>Single: one party is unaware of group assignments (generally participants);</br>Double: two parties are unaware of group assignments (generally the participants and the researchers); </br>Triple: concealing group assignment from additional parties No
Is randomized Yes
Cross-over Participants alternate between different treatment groups or conditions over a specified period, allowing each participant to serve as their own control No
Number of arms -999

Study characteristics

Inclusion criteria ?
Exclusion criteria ?
N randomized -999
Analysis PP: Per Protocol analysis, i.e. only participants included who adhered to the study protocol.</br>ITT: Intention-to-treat analysis, i.e. all randomized participants included regardless of any drop-outs or changes in assignment.</br>mITT: modified Intention-to-treat analysis can refer to analyses in which participants with missing outcome data are excluded or it can refer to analyses in which only participants who received at least one treatment dose are included. In this case, participants dropped out of the study prematurely for reasons unrelated to the treatment. ?
Specifications on analyses ?
Countries of data collection ?
LoE Level of evidence ?
Outcome timeline Data collection times ?

Characteristics of participants

Setting Refers to cancer therapy setting.</br>- Curative therapy: aims to completely eradicate a disease and achieve a full recovery; </br>- Neo-adjuvant therapy: form of curative therapy, given before the primary treatment for cancer (usually surgery); </br>- Adjuvant therapy: form of curative therapy, given after the primary treatment for cancer (usually surgery); </br>- Palliative therapy: focuses on providing relief from symptoms and improving the quality of life for patients, without necessarily targeting the underlying disease; </br>- Active surveillance: involves close monitoring of disease progression without any intervention (typically used for prostate cancer);</br>- No therapy setting: Patients who completed therapy/are currently not in cancer treatment, cancer survivors. ?
Types of cancer "Other Cancers" means that only a subpopulation was specified, but further unspecified cancer types were included ?
Cancer stages Early Stage: generally refers to cancer that is localized to the area where it started, mostly stages I and II;</br>Advanced Stage: cancer that has spread beyond its original site, mostly stages III and IV, with stage IV indicating distant metastasis ?
Specifications on cancer stages ?
Comorbidities ?
Current cancer therapies ?
Specifications on cancer therapies ?
Previous cancer therapies ?
Gender ?
Gender specifications ?
Age groups
Age groups specification ?

Arms

Outcomes

Funding and Conflicts of Interest

Funding ?
Conflicts of Interest ?

Further points for assessing the study

Sample

Power analysis performed ?
- Sample size corresponds to power analysis ?
- Reasons for insufficient sample size based on power analysis ?
If no power analysis performed: at least moderate sample size (n >= 30 per arm) ?
Ethnicity mentioned ?

Alternative Explanation

Other explanations for an effect besides the investigated intervention ?
- Possibility of attention effects ?
- Possibility of placebo effects ?
- Other reasons ?

Statistics

Correct use of parametric and non-parametric tests Testing for normal distribution only necessary if parametric tests are used, NI: use of parametric tests without report of normal distribution testing ?
Correction for multiple testing ?
Measurement of compliance ?
Consistent reporting in numbers (figures, flowchart, abstract, results) ?
Comprehensive and coherent reporting ?
Cross-over ?
- Sufficient washout period ?
- Tested for carry-over effects ?
- Tested for sequence effects ?

Interpretation of results

Effect sizes reported (clinical vs. statistical significance) ?
Side effects systematically recorded ?
Side effects considered in result interpretation ?
Ethics votum ?


Additional Notes

?